Royalty Pharma (RPRX) Liabilities and Shareholders Equity (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $19.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 12.53% year-over-year to $19.8 billion; the trailing twelve-month figure through Mar 2026 stood at $77.1 billion (up 7.8% YoY), and the FY2025 full-year result was $19.6 billion, up 7.67% from the prior year.
• Liabilities and Shareholders Equity rose to $19.8 billion in Q1 2026, from $19.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $19.8 billion in Q1 2026 to a low of $15.9 billion in Q3 2023.
• A 5-year average of $17.7 billion and a median of $17.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity declined 10.28% in 2023 and climbed 13.79% in 2024, its largest moves.
• Tracing RPRX's Liabilities and Shareholders Equity over 5 years: stood at $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then increased by 11.24% to $18.2 billion in 2024, then advanced by 7.67% to $19.6 billion in 2025, then rose by 0.99% to $19.8 billion in 2026.
• Business Quant data shows RPRX's Liabilities and Shareholders Equity at $19.8 billion in Q1 2026, $19.6 billion in Q4 2025, and $19.3 billion in Q3 2025.